KalVista Pharmaceuticals Valuation Multiples

Discover KalVista Pharmaceuticals' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Zhejiang Jolly, SOTHEMA, Chengdu Easton, Concord Biotech and more.

KalVista Pharmaceuticals Overview

About KalVista Pharmaceuticals

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.


Founded

2004

HQ

United States

Employees

270

Financials (FY)

Revenue: -
Net Income: -

EV

$1.3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals has current market cap of $1.4B, and enterprise value of $1.3B.

Market Cap Evolution


KalVista Pharmaceuticals' stock price is $27.00.

KalVista Pharmaceuticals share price increased by 98.1% in the last year.

See more trading valuation data for KalVista Pharmaceuticals
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1.3B$1.4B0.0%-1.3%98.1%-

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

KalVista Pharmaceuticals Valuation Multiples

KalVista Pharmaceuticals Financial Valuation Multiples

As of July 19, 2026, KalVista Pharmaceuticals has market cap of $1.4B and EV of $1.3B.

LTMLast FY202320242025202620272028

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified KalVista Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

KalVista Pharmaceuticals Competitors

KalVista Pharmaceuticals competitors include Zhejiang Jolly, SOTHEMA, Chengdu Easton, Concord Biotech, Absci, Ab&B Bio-Tech, Hualan Biological Vaccine, Pharma Mar, Aktis Oncology and Neuren Pharma.

Most KalVista Pharmaceuticals public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Zhejiang Jolly3.2x2.9x11.5x10.5x
SOTHEMA4.3x3.8x19.1x-
Chengdu Easton6.1x5.7x20.5x20.0x
Concord Biotech12.7x12.1x32.5x34.0x
Absci458.5x292.8x(12.4x)(11.7x)
Ab&B Bio-Tech41.5x-(59.2x)-
Hualan Biological Vaccine6.7x6.8x24.3x25.1x
Pharma Mar5.4x5.6x17.0x19.8x

This data is available for Pro users. Sign up to see all KalVista Pharmaceuticals competitors and their valuation data.

Start Free Trial

KalVista Pharmaceuticals VC Funding History

Before going public, KalVista Pharmaceuticals raised $33M in total equity funding, across 1 round.


KalVista Pharmaceuticals Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jul-15Series BNovo Holdings; SV Health Investors; Longwood Fund; Venrock; RA Capital Management$33M-KalVista Pharmaceuticals announced a Series B financing round raising $33 million to advance development of its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE). The round was led by RA Capital Management and included participation from existing investors Novo A/S and SV Life Sciences, along with new investors Longwood Fund and Venrock. Rajeev Shah from RA Capital and Rich Aldrich from Longwood Fund joined KalVista's Board of Directors, while Bong Koh from Venrock and Tomas Kiselak from RA Capital joined as Board observers. CEO Andrew Crockett stated that the financing would allow the company to rapidly advance its programs toward clinical proof-of-concept milestones and bring treatments to patients with serious diseases. The syndicate brought considerable experience in plasma kallikrein-targeted mechanisms and small molecule drug development.

Acquisitions by KalVista Pharmaceuticals

KalVista Pharmaceuticals has acquired 1 company to date.

Last acquisition by KalVista Pharmaceuticals was on June 15th 2016. KalVista Pharmaceuticals acquired Carbylan Therapeutics for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by KalVista Pharmaceuticals

Carbylan Therapeutics
Description
Carbylan Therapeutics is a Palo Alto-headquartered clinical-stage biopharmaceutical company developing combination therapies for underserved markets. Founded in 2004, it advances proprietary formulations targeting pain management and gastrointestinal disorders through late-stage trials in the United States.
HQ CountryUnited States
HQ City
San Francisco, CA
Deal Date15 Jun 2016
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all KalVista Pharmaceuticals acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About KalVista Pharmaceuticals

When was KalVista Pharmaceuticals founded?KalVista Pharmaceuticals was founded in 2004.
Where is KalVista Pharmaceuticals headquartered?KalVista Pharmaceuticals is headquartered in United States.
How many employees does KalVista Pharmaceuticals have?As of today, KalVista Pharmaceuticals has over 270 employees.
Who is the CEO of KalVista Pharmaceuticals?KalVista Pharmaceuticals' CEO is Benjamin L. Palleiko.
Is KalVista Pharmaceuticals publicly listed?Yes, KalVista Pharmaceuticals is a public company listed on Stuttgart Stock Exchange.
What is the stock symbol of KalVista Pharmaceuticals?KalVista Pharmaceuticals trades under 4XC1 ticker.
When did KalVista Pharmaceuticals go public?KalVista Pharmaceuticals went public in 2015.
Who are competitors of KalVista Pharmaceuticals?KalVista Pharmaceuticals main competitors include Zhejiang Jolly, SOTHEMA, Chengdu Easton, Concord Biotech, Absci, Ab&B Bio-Tech, Hualan Biological Vaccine, Pharma Mar, Aktis Oncology, Neuren Pharma.
What is the current market cap of KalVista Pharmaceuticals?KalVista Pharmaceuticals' current market cap is $1.4B.
Is KalVista Pharmaceuticals profitable?No, KalVista Pharmaceuticals is not profitable.
How many companies KalVista Pharmaceuticals has acquired to date?As of July 2026, KalVista Pharmaceuticals has acquired 1 company.
What was the largest acquisition by KalVista Pharmaceuticals?None of the M&A deals KalVista Pharmaceuticals has completed have disclosed valuations.
What companies KalVista Pharmaceuticals acquired?KalVista Pharmaceuticals acquired Carbylan Therapeutics.
In how many companies KalVista Pharmaceuticals has invested to date?KalVista Pharmaceuticals hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to KalVista Pharmaceuticals

Lists including KalVista Pharmaceuticals

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial